CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Apple Watch Series 5Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation

Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug229 CAStem Wiki 1.00

Correlated MeSH Terms (7)

Name (Synonyms) Correlation
D055370 Lung Injury NIH 0.23
D011024 Pneumonia, Viral NIH 0.14
D013577 Syndrome NIH 0.13
D055371 Acute Lung Injury NIH 0.12
D012127 Respiratory Distress Syndrome, Newborn NIH 0.12
D012128 Respiratory Distress Syndrome, Adult NIH 0.10
D011014 Pneumonia NIH 0.07

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0002090 Pneumonia HPO 0.07

There is one clinical trial.

Clinical Trials

1 CoronaWatch - Early Detection of Cardiovascular Risks in COVID-19 Via SmartWatch

In December 2019, a new viral disease called COVID-19 emerged. It is caused by the new corona virus SARS-CoV-2. It was initially described in the chinese city of Wuhan. In the following months, the disease developed into a pandemic, which is currently an immense international challenge. So far, there is little scientific evidence on risk stratification, especially on the prognostic value of biomarkers (laboratory-chemical, clinical and digital) with regard to clinical deterioration of patients with COVID-19. Further scientific studies are needed to establish optimal risk stratification and early detection of clinical deterioration. In this study, the investigators aim to observe patients with COVID-19 via SmartWatches on top of their clinical routine. The investigators aim to determine, whether the addition of SmartWatches enhances risk stratification, early detection of complications and prognostics in patients with COVID-19, who have cardiovascular diseases or receive medication with arrhythmogenic risk.

NCT04376853 COVID-19 Device: Apple Watch Series 5

Primary Outcomes

Description: Identification of biomarkers (laboratory-chemical, clinical, digital) for risk stratification, early detection of complications and prognosis

Measure: Biomarker

Time: 3 months

Secondary Outcomes

Description: Identification of laboratory-chemical, clinical or digitally measured protective factors, that indicate good prognosis

Measure: Protective factors

Time: 3 months

Description: The amount of time is compared between participants regarding the wearing of a SmartWatch as a monitoring tool

Measure: SmartWatch compliance

Time: 3 months

Description: Detection of an irregular heartbeat (PPG) as a sign of atrial or ventricular arrhythmias and correlation to intermittently recorded ECGs by SmartWatch

Measure: Arrhythmias

Time: 3 months

Description: Detection of QT time changes (prolongation) in intermittently recorded ECGs by SmartWatch and correlation with clinical variables (change of medication, fever, etc.)

Measure: QT time changes

Time: 3 months

Description: Application of artificial intelligence and machine learning techniques for longitudinal risk models by using collected data (e.g. metabolomics)

Measure: Longitudinal risk models

Time: 3 months

No related HPO nodes (Using clinical trials)